Why Vertex Hit a Home Run With Its Q3 Results, but Few Are Cheering

Keith Speights, The Motley Fool
·3 min read
Why Vertex Hit a Home Run With Its Q3 Results, but Few Are Cheering
Why Vertex Hit a Home Run With Its Q3 Results, but Few Are Cheering

Vertex Pharmaceuticals' (NASDAQ: VRTX) great year screeched to a halt a couple of weeks ago. The company pulled the plug on a phase 2 study evaluating alpha-1 antitrypsin deficiency (AATD) candidate VX-814 because of safety concerns.